

Recommended protocol for A2MG Nebulisation in Equine Asthma

This is the recommended protocol for use of A2MG in clinical cases of Equine Asthma:

- The autologous A2MG product should be prepared from horse's blood following the standard protocol in terms of patient guidelines, processing, handling and storage recommendations. This information can be found on the kit insert or on the Nupsala website, nupsala.com
- The final A2MG product can be put into 3-4mL aliquots. If starting an initial course, one 3-4mL aliquot should be kept available for the first administration. The rest of the product can be stored frozen into 3-4mL aliquots for subsequent administrations.
- Standard administration consists of 3-4 mL of A2MG product diluted with an equivalent amount (3-4 mL) of sterile physiological saline (0.9%) or Lactated Ringer's Solution (LRS), resulting in a total volume of 6-8mL per administration. Larger volumes of saline or LRS (to achieve a 1:2 dilution) can be used to reduce the viscosity of the product and facilitate administration (eg 3-4mL of A2MG diluted with 6-8mL of saline or LRS).
- A total of 6-8 administrations, given at 48 to 72-hour intervals, is recommended for the initial cycle. The final decision on number of administrations can be made according to progress.
- A second cycle can be administered after the initial course if necessary. The recommended protocol is 2mL of A2MG product + 6mL dilution with 0.9% saline or LRS; administered at 48-72 hour intervals, 6-8 times.
- The A2MG product should be administered via nebulization using the Flexineb delivery system (or a suitable alternative). Hand walking during administration may help to optimise delivery.
- Horses receiving concurrent treatment for equine asthma can continue their existing therapy alongside A2MG application.
- In cases of severe equine asthma, horses may benefit from initial stabilisation with conventional drugs (e.g. bronchodilators and corticosteroids) and/or additional treatments beyond the initial series of A2MG.

The use of A2MG in the treatment and management of Equine Asthma cases has shown positive benefits. Controlled clinical trials are in progress and these are likely to provide more and ongoing information on use. Equine Asthma (EA) can manifest as a spectrum of clinical signs in terms of severity, response to treatment and requirement for ongoing therapy. The above guidelines are therefore intended for general use; with all treatment and maintenance administrations made on an individual basis and under veterinary guidance.

Following stabilisation with initial treatment cycles and for horse's requiring 'maintenance therapy', clinical experience has shown that a single administration of A2MG, given at ~ monthly intervals, can be beneficial. This would consist of 3-4mL of A2MG product diluted with 0.9% NaCl or LRS and nebulised as per previous recommendations.

A2MG nebulization is permitted for use under competition rules provided administration guidelines and preparation protocols are strictly followed (to ensure the final product is free from prohibited agents).

Actively competing horses may benefit from a single administration A2MG prior to competition. This may be particularly beneficial for horses that exhibit exercise induced pulmonary haemorrhage (EIPH).

Updated 01/10/2026